Background
==========

Bcl-3 was originally identified as expressed in chronic B cell lymphocytic leukemia \[[@B1]\]. Many cell growth and survival promoters can induce Bcl-3 expression, and Bcl-3 overexpression has been detected in other cancers such as nasopharyngeal carcinoma (NPC) \[[@B2],[@B3]\]. Nedd4 binding protein 2 (N4BP2, GenBank:[AY267013](AY267013)) is a Bcl-3 binding protein, N4BP2 protein contains a polynucleotide kinase domain (PNK) at the N-terminus and a Small MutS Related (Smr) domain with nicking endonuclease activity near C-terminus \[[@B3]\]. MutS is central to the DNA mismatch repair (MMR) systems that are responsible for maintaining genome stability and protecting against mutation, Mutations in these genes are linked to the development of certain types of cancer \[[@B4],[@B5]\]. Since N4BP2 contains a MutS-related domain, N4BP2 may play a role in MMR.

NPC is an epithelial tumor with an exceptionally high incidence in southern China, particularly in the Guangdong province \[[@B6],[@B7]\]. Etiological and epidemiological studies have suggested that susceptibility genes may determine the predisposition to developing NPC \[[@B8],[@B9]\]. Previously, we reported the use of 382 polymorphic microsatellite markers to identify a candidate susceptibility locus that mapped to chromosome 4p15.1-q12 (D4S2950-D4S2916) in a subset of NPC families \[[@B10]\]. Further analysis identified SNPs within or near this region, strongly suggesting the presence of an NPC susceptibility locus adjacent to the LOC344967 \[[@B11]\], very close to the *N4BP2*gene.

We thus hypothesized that SNPs or other variation in the *N4BP2*gene lead to a predisposition to developing NPC. We further hypothesized that the *N4BP2*gene plays a role in tumorigenesis. To address these hypotheses, we examined *N4BP2*haplotypes among NPC patients from southern China. We also examined mRNA levels of *Bcl-3*and *N4BP2*in NPC cell lines and tissues.

Methods
=======

Subjects
--------

A total of 531 sporadic NPC patients and 480 unrelated age, sex-, and geographically-matched healthy individuals from southern China were used for our case-control study. NPC patients were recruited from Sun Yat-sen University Cancer Center and the presence of differentiated non-keratinizing NPC or undifferentiated NPC was confirmed by histological analysis. Control subjects were recruited from the People\'s Hospital of Guangdong Province. The characteristics of cases and controls are shown in Table [1](#T1){ref-type="table"}. Although the incidence of NPC is generally higher among males than females, no significant difference in sex distribution existed between case and control groups in this study. The average age in the control group was 37 ± 10, and in the case group was 40 ± 10; thus the age distribution here is a good representation of the broader NPC patient population given that NPC incidence peaks at the relatively young age of 45.

###### 

Profile of the study subjects

  Characteristic         Control (n = 480)   Case (n = 531)   Chi square   *p*^a^
  ---------------------- ------------------- ---------------- ------------ --------
  Gender (Male/Female)   354/126             390/141          0.01         0.91
  Age                    37 ± 10             40 ± 10          0.86         0.44

^a^*p*value obtained from Chi-square Test

DNA preparation
---------------

Genomic DNA was extracted from 5--10 ml peripheral blood using the QIAamp DNA Blood Midi kit (Qiagen, German).

Primer design
-------------

Between 250 and 400 bp of sequence surrounding SNPs sites were submitted to the primer design program \[[@B12]\]. The primers used for SNPs are shown in Table [2](#T2){ref-type="table"}.

###### 

Primers used for SNPs

  Number   RefSNP(RS) (NCBI)    Forward primers(5\'→3\')   Reverse primer(5\'→3\')       Product size (bp)
  -------- -------------------- -------------------------- ----------------------------- -------------------
  SNP1     RS17439810           agctgacagtgttcggctct       ggtcaacatgatgtccgaaa          257
  SNP2     loc123-e3l-snp2^a^                                                            
  SNP3     RS17511578           cttctcgtcctgggtctcc        TGTCAGCTACAGCCAGTCCA          397
  SNP4     RS17585937           acatgggccacaggaagtg        aggcctgccagacacctg            266
  SNP6     RS17511668-SNP2^b^   TCTGTTCAATGCAAAATCCAA      catcttGTGAAGGCAAAAATGA        389
  SNP7     RS794001-SNP1^c^     GCTTCATATATGCCAAGCATCA     TTTTCTTCTTTTGTTTAAATCTGCATT   398
  SNP9     RS2252352            agaTGCAGCTCAATCACCTA       CAGAAGAAATTGCCTTACAGGA        300
  SNP10    RS2271395            tccagtctagtcaaaatggtgaga   aacacacagtgcaatttcttaactg     243
  SNP11    RS1442855            TCATTTGCTTCAGCTTGTCA       GGCCTTAAACCTTACTCCATCC        300
  SNP12    RS2347044            TCTTGTGGTGAAATGTAGAATGC    CCTGAGATTAACTACCCATATCAGC     368

^a^Primers for loc123-e3l-snp2 are same as RS17439810.

^b^primers for RS17511668-SNP2 are same as RS17511668

^c^RS794001-SNP1 are same as RS794001.

PCR Amplification
-----------------

Long-distance PCR was performed in a total volume of 15 μl containing 200 ng of genomic DNA, 1.5 μl 10× Buffer, 50 μM dNTPs, 0.3 μM each primer, and 1U Taq DNA polymerase. Samples were amplified with each pair of primers described above as follows: 94°C for 3 min, 10 cycles of 94°C for 30 s, 63°C for 1 min, and 72°C for 1 min; 25 cycles of 94°C for 30 s, 58°C for 1 min, 72°C for 1 min, and a final extension at 72°C for 7 min. First-round PCR products were diluted 5-fold for the second-round of PCR. Round 2 PCR conditions were 94°C for 3 min, 10 cycles at 94°C for 30 s, 65°C for 1 min, and 72°C for 1 min; 30 cycles at 94°C for 30 s, 62°C for 1 min, and 72°C for 1 min, and 72°C for 7 min. PCR products were visualized on a 1.2% agarose gel, stained with ethidium bromide, and visualized by a transilluminator.

Genotyping
----------

PCR products were sequence using ABI377 or ABI3730 sequencers (PE Applied biosystem). Base calling, contig assembly contigs, and mutation detection was performed using Polyphred package (Polyphred, Phred/Phrap/Consed) \[[@B13]\]. All traces were visually inspected by at least two observers.

Statistical methods
-------------------

Unrelated control samples were selected for analysis using the Hardy-Weinberg Equilibrium (HWE) test using an exact test. Standard EM algorithm was used to infer haplotype and estimate population frequency. Single marker and haplotype association test and significance estimation were performed using a permutation test.

Cell Culture and Treatment
--------------------------

NP69 (an SV40 large T antigen-immortalized nasopharyngeal epithelial cell line) and NP69-LMP1 (NP69 cells transfected with the *LMP1*gene) were cultured in Keratinocyte-SFM medium (GibcoBRL) with Bovine Pituitary Extract and rEGF. C666-1 (a poorly differentiated nasopharyngeal epithelial cell line carrying the Epstein-Barr virus) was grown in RPMI 1640 supplemented with 10% fetal bovine serum (FBS, Hyclone, Utah, USA). CNE-1 (a highly-differentiated nasopharyngeal epithelial cell line), CNE-2 (a poorly differentiated nasopharyngeal epithelial cell line) and Sune(a poorly differentiated nasopharyngeal epithelial cell line carried Epstein-Barr virus) were maintained in RPMI 1640 with 10% FBS.

Tissue collection and RT-PCR
----------------------------

A total of 21 tissues were collected from Sun Yat-sen University Cancer Center. Six paired matched tissues from different organs included esophagus, stomach, liver, lung, cervix and breast; nine nasopharyngeal tissues contained 2 chronic nasopharynx inflammation (Inf.), 1 Differentiated Carcinoma (DNK), 4 Undifferentiated Carcinoma (NDNK), 1 low differentiated squamous carcinoma (LDS) and 1 non-Hodgkin\'s lymphoma (NHL). RNA was extracted using TRIZOL Reagent (Invitrogen, Carlsbad, CA), and reverse transcription was performed using the TaKaRa RNA PCR kit (AMV) Ver.3.0 (TaKaRa BIO, Shiga, Japan). PCR to detect *N4BP2*was performed using the following primers (*N4BP2-L*: 5\'-AAAGGGAGACCCTTATGTTTGA-3\'; *N4BP2-R*: 5\'-AAATCAAACCTCACTTGCATTT-3\') and *Bcl*-3 with primers (*Bcl-3-L*:5\'-tcctctggtgaacctgccta-3\'; *Bcl-3-R*:5\'-gaagaccattggagctgagg-3\') and *β-actin*as control with primers (5\'-acactgtgcccatctacgagggg-3\' and 5\'-atgatggagttgaaggtagtttcgtggat-3\').

Results
=======

SNP analysis
------------

We identified a total of twelve SNP associated with the *N4BP2*locus, four of which were upstream of the *N4BP2*gene and eight which were within *N4BP2*gene (Table [3](#T3){ref-type="table"}). Of the SNPs, five SNPs resulted in missense mutations. Three novel SNPs were identified: loc123-e3l-snp2 (position 39868005, allele A/G, resulting in amino acid change Met171 to Val), RS17511668-SNP2 (position 39926432, allele G/A, amino acid change Glu118 to Lys), and RS794001-SNP1 (position 39944127, allele T/G, intronic). However, allele frequency analysis revealed no significant difference between case and control groups (Table [4](#T4){ref-type="table"}).

###### 

Candidate SNPs

  Number     RefSNP                Contig Position   Variant Alleles   Amino acid change   MAF         HWpval      Genotyped (%)
  ---------- --------------------- ----------------- ----------------- ------------------- ----------- ----------- ---------------
  SNP1       RS17439810            39867905          C, G              Gln104Glu           0.058       0.195       74.0
  **SNP2**   **loc123-e3l-snp2**   **39868005**      **A, G**          **Met171Val**       **0.271**   **0.999**   **81.4**
  SNP3       RS17511578            39868252          A, C              Asn189His           0.063       0.978       74.8
  SNP4       RS17585937            39868402          G, A              5\'UTR              0.118       1.000       76.2
  **SNP6**   **RS17511668-SNP2**   **39926432**      **G, A**          **Glu118Lys**       **0.067**   **1.000**   **89.9**
  **SNP7**   **RS794001-SNP1**     **39944127**      **T, G**          **intron**          **0.054**   **0.562**   **97.4**
  SNP9       RS2252352             39950655          T, T              intron              0.368       0.327       96.1
  SNP10      RS2271395             39961241          G, A              Ala1587Thr          0.368       1.000       94.8
  SNP11      RS1442855             43164843          G, A              intron              0.164       0.946       82.5
  SNP12      RS2347044             43273849          A, G              intron              0.225       0.377       96.9

RefSNP(RS), SNP accession ID; HWpval, *P*value of Hardy-Weinberg equilibrium tests for control subjects; MAF, minor allele frequency; % Genotyped, Percent of samples successfully genotyped. New SNPs are shown in bold.

###### 

SNP allele frequency comparison between cases and controls

  Number   Name              Major Alleles   Case, Control Ratios^a^   Chi square   P value
  -------- ----------------- --------------- ------------------------- ------------ ---------
  SNP1     loc123-e3l-snp1   C, C            772:42 452:34             1.864        0.1722
  SNP2     loc123-e3l-snp2   A, A            570:224 472:164           1.051        0.3053
  SNP3     loc123-e3l-snp3   G, G            659:51 572:32             1.960        0.1615
  SNP4     LOC344967         G, G            634:74 546:84             2.658        0.1031
  SNP6     RS17511668-SNP2   G, G            802:66 670:40             2.419        0.1199
  SNP7     RS794001-SNP1     T, T            890:48 728:44             0.282        0.5954
  SNP9     RS2252352         T, T            574:320 493:301           0.809        0.3684
  SNP 10   RS2271395         A, A            599:331 452:282           1.410        0.2350
  SNP 11   RS1442855         G, G            646:128 565:109           0.035        0.8513
  SNP 12   RS2347044         A, A            712:212 607:171           0.225        0.6351

^a^Case, Control Ratios = the frequency of Major Alleles: the frequency of Minor Alleles

Haplotype analysis
------------------

Haplotype frequencies and distributions were estimated using a standard EM algorithm. Interestingly, Four SNPs (SNP6-7-9-10) combined haplotype Block 2 ATTA and GTTG exhibited notable difference between case and control groups (Table [5](#T5){ref-type="table"}). Permutation tests for allelic association confirmed that block ATTA and GTTG are closely linked (Table [6](#T6){ref-type="table"}) and confirmed the difference of Block 2 ATTA and GTTG in cases and controls.

###### 

Haplotype analysis

  Block            Haplotype   Frequencies^a^   Case, Control Ratios^b^     Chi Square   P Value
  ---------------- ----------- ---------------- --------------------------- ------------ --------------
  1(SNP1-4)                                                                              
                   CAG         0.55             519.0:411.0, 420.2:357.8    0.557        0.4556
                   CGG         0.272            261.2:668.8, 204.2:573.8    0.724        0.3947
                   CAA         0.119            100.6:829.4, 103.0:675.0    2.368        0.1238
                   GAG         0.058            49.2:880.8, 50.6:727.4      1.149        0.2837
  2(SNP6-7-9-10)                                                                         
                   GTTA        0.542            521.4:426.6, 429.0:377.0    0.549        0.4589
                   GTCG        0.355            328.2:619.8, 294.3:511.7    0.684        0.4082
                   AGTA        0.047            40.4:907.6, 41.6:764.4      0.806        0.3692
                   **ATTA**    **0.017**        **27.4:920.6, 2.7:803.3**   **16.903**   **3.93E-05**
                   **GTTG**    **0.016**        **4.6:943.4, 23.3:782.7**   **16.038**   **6.21E-05**
                   GTCA        0.015            13.1:934.9, 12.9:793.1      0.14         0.7079

Bold type indicates significant difference between case and control.

^a^frequency of haplotype in total subjects.

^b^frequency of haplotype: frequency of non-haplotype.

###### 

Permutation test

  Name                            Chi Square   Permutation p-value
  ------------------------------- ------------ ---------------------
  **Block 2: ATTA**               **16.903**   **0.0007**
  **Block 2: GTTG**               **16.038**   **0.0013**
  Block 1: CAA                    2.368        0.8602
  Block 1: GAG                    1.149        0.9916
  Block 2: AGTA                   0.806        0.9992
  Block 1: CGG                    0.724        0.9997
  Block 2: GTCG                   0.684        0.9998
  Block 1: CAG                    0.557        1
  Block 2: GTTA                   0.549        1
  Block 2: GTCA                   0.14         1
                                               
  LOC344967                       2.658        0.8071
  RS17511668-SNP2                 2.419        0.8498
  loc123-e3l-snp3                 1.96         0.9218
  loc123-e3l-snp1                 1.864        0.9366
  RS2271395                       1.41         0.9807
  loc123-e3l-snp2                 1.051        0.9952
  RS2252352                       0.809        0.9991
  RS794001-SNP1                   0.282        1
  RS1442855                       0.035        1
  RS2347044                       0.225        1
  10000 permutations performed.                

Haplotype in bold is closely linked block

N4BP2 and Bcl-3 expressed in cells and tissues
----------------------------------------------

*Bcl-3*and *N4BP2*were detected in all cell lines examined (Figure [1A](#F1){ref-type="fig"}). Interestingly, gene expression levels appeared to vary among the cell lines, with the lowest levels being detected in the Sune line. *N4BP2*and *Bcl-3*mRNA levels appeared to be higher in tumor than in matched normal tissue (Figure [1B](#F1){ref-type="fig"}). *N4BP2*and *Bcl-3*were also detected in nasopharyngeal tissues (Figure [1C](#F1){ref-type="fig"}). These observations suggest that *N4BP2*expression levels correlate with the progression of cancer including NPC.

![**Expression of *N4BP2*and *Bcl-3*mRNA in cells and tissues**. (A) Expression of *N4BP2*and *Bcl-3*mRNA in nasopharyngeal epithelial cell lines. RT-PCR was performed with gene-specific primers and *β-actin*was used as a control. (B) Expression of *N4BP2*and *Bcl-3*mRNA in matched tissues. RT-PCR was performed with gene-specific primers and *β-actin*as a control. up-low: normal tissue; down-low: tumor tissue. (C) Expression of *N4BP2*and *Bcl-3*mRNA nasopharyngeal tissues. Inf.: chronic nasopharynx inflammation; NDNK: Undifferentiated Carcinoma; DNK: Differentiated Carcinoma; LDS: Low differentiated squamous carcinoma; NHL: non-Hodgkin\'s lymphoma.](1479-5876-5-36-1){#F1}

Discussion
==========

We previously showed, by linkage analysis that an NPC susceptibility locus maps to chromosome 4 near the *LOC344967*. Here, we extend this analysis in an effort to identify a bona fide NPC susceptibility gene. *N4BP2*is a candidate gene in this region, and we thus sought to examine the correlation between genetic polymorphisms in *N4BP2*, a mismatch repair gene, and the incidence of NPC. SNPs have been shown to be extremely useful for studying the association between genomic regions and disease \[[@B14]\]. Several studies have demonstrated that polymorphic variation in mismatch repair genes contributes to susceptibility to certain cancers \[[@B15],[@B16]\]. In addition, several pieces of evidence suggest that nasopharyngeal carcinogenesis is associated with individual susceptibility caused by SNPs. Our results show that, although there is no significant difference in SNPs between cases and controls, there are two haplotypes, ATTA and GTTG, the distribution of which differed between case and control groups. Just as the report that almost not any difference in the allele frequencies of five SNPs within the *TNFSF4*gene individuals suffered from coronary artery disease versus the controls while there were significantly more frequent of the possible haplotypes from this five TNFSF4 SNPs in individuals with coronary artery disease than controls \[[@B17]\]. Insight into this paradox has been provided in a recent review by Schaid \[[@B18]\]. Haplotypes, the grouping of closely linked alleles on a chromosome, make an important contribution to the study of the genetic basis of disease. Schaid \[[@B18]\] explained that for case-control studies, methodological approach based on haplotype has more advantage than single-locus analysis as the SNPs are in LD with a causative diallelic locus; in particular, haplotype-based methods have greater power when the marker alleles are in strong LD with causative alleles. Haplotype methods are more useful for variants which are more recently evolved, rarer and more causative than for variants which are older and more common. This may help explain why the haplotypes ATTA and GTTG exhibit differences in frequency between case and control groups while individual SNPs do not.

N4BP2 is a Bcl-3 binding protein, and Bcl-3 is an oncoprotein that is overexpressed in certain cancers, including NPC. Our analysis of *N4BP2*and *Bcl-3*expression levels suggest that expression of these genes is correlated, suggesting they may be co-regulated. We also found that *N4BP2*and *Bcl-3*are expressed in all NPC cell lines examined and were higher for certain cancers. These observations are consistent with previous reports.

Conclusion
==========

Above all, we found that two *N4BP2*haplotypes, ATTA and GTTG, are correlated with NPC. This will be useful for predict the development of NPC. In addition, *N4BP2*and *Bcl-3*mRNA levels were elevated in tumors, including NPC tumors, which suggest new therapeutic targets for fighting NPC.
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